Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
116076 trials found · Page 378 of 5804
-
New hope for liver cancer: drug combo targets tumors after immunotherapy fails
Disease control Recruiting nowWhile immune-based therapies (including targeted-immune or dual-immune regimens) have become first-line standard for advanced hepatocellular carcinoma (HCC), there is a lack of high-level evidence to guide second-line treatment after progression on immune checkpoint inhibitors (I…
Phase: PHASE2 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Jun 27, 2026 07:58 UTC
-
New hope for advanced prostate cancer: experimental drug cocktails enter human testing
Disease control Recruiting nowThis study is an open-label, multicenter Phase Ib/II clinical trial designed to evaluate the safety, tolerability, pharmacokinetics, and preliminary anti-tumor activity of QLC5508 in combination with NHA (abiraterone or enzalutamide), QLC5508 in combination with QLH12016, QLC5508…
Phase: PHASE1, PHASE2 • Sponsor: Qilu Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 13:01 UTC
-
New combo aims to melt fat, save muscle in obesity battle
Disease control Recruiting nowIn adults with obesity seeking treatment, weight loss would ideally be composed almost exclusively of fat mass. However, loss of muscle mass and bone are unintentional consequences of weight loss, which may have negative effects on health by lessening improvements in glucose and …
Phase: PHASE2 • Sponsor: Massachusetts General Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:01 UTC
-
Stroke drug hope: new window of 24 hours for treatment
Disease control Recruiting nowThis study aims to evaluate the efficacy and safety of tenecteplase (TNK) intravenous thrombolysis within the extended time window (4.5 to 24 hours) in patients with acute posterior circulation ischemic stroke.
Phase: NA • Sponsor: The First Affiliated Hospital of University of Science and Technology of China • Aim: Disease control
Last updated Jun 27, 2026 13:04 UTC
-
RNA clues may unlock hidden genetic causes of developmental disorders
Diagnosis Recruiting nowThree million persons in France are impacted by rare diseases. Amid the 7000 different diseases which are identified today, neurodevelopmental disorders are the main symptoms found interesting 35 000 birth every years, according to the French Health Authority. In half of these ca…
Phase: NA • Sponsor: University Hospital, Angers • Aim: Diagnosis
Last updated Jul 01, 2026 00:00 UTC
-
AI-Powered ECGs could spot silent heart disease before It's too late
Diagnosis Recruiting nowThis study aims to improve the early detection of undiagnosed heart disease, which causes serious health issues, hospital admissions, and high healthcare costs. Researchers are exploring how artificial intelligence (AI) can analyse routine heart tests, called electrocardiograms (…
Sponsor: Imperial College London • Aim: Diagnosis
Last updated Jun 27, 2026 11:00 UTC
-
Precision radiation plus immunotherapy shows promise for bile duct cancer
Disease control Recruiting nowThe primary objective of this study is to evaluate the efficacy and safety of PULSAR in combination with dual immune checkpoint inhibitors (PD-1 monoclonal antibody + CTLA-4 monoclonal antibody) and GC chemotherapy in patients with locally advanced or metastatic cholangiocarcinom…
Phase: PHASE1, PHASE2 • Sponsor: Wang Xin • Aim: Disease control
Last updated Jun 27, 2026 08:05 UTC
-
Promising new combo tackles advanced stomach cancer in early trial
Disease control Recruiting nowThe goal of this Phase II clinical trial is to evaluate the efficacy and safety of Iparomlimab and Tuvonralimab (QL1706) combined with SOX chemotherapy (S-1 plus Oxaliplatin) in patients with previously untreated advanced or metastatic gastric cancer or gastroesophageal junction …
Phase: PHASE2 • Sponsor: Beijing Friendship Hospital • Aim: Disease control
Last updated Jun 27, 2026 08:08 UTC
-
Balloon blasts fat in arteries: could it prevent heart attacks?
Disease control Recruiting nowThe goal of this clinical trial is to find out whether treating vulnerable plaques in the coronary arteries with a drug-coated balloon can make them less dangerous than using standard medication alone. The study includes adults with acute coronary syndrome (a type of heart proble…
Phase: NA • Sponsor: Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) • Aim: Disease control
Last updated Jun 27, 2026 08:11 UTC
-
AI tool could revolutionize skin cancer detection in family clinics
Diagnosis Recruiting nowBackground: Artificial intelligence has in numerous studies shown high accuracy in detecting skin cancer when trained on various databases of dermatoscopic images. However, there are very few prospective studies conducted in real clinical settings directed at patients seeking hea…
Phase: NA • Sponsor: Linkoeping University • Aim: Diagnosis
Last updated Jun 27, 2026 08:10 UTC
-
Gene therapy shot aims to tame autoimmune diseases in early trial
Disease control Recruiting nowThis study is designed as a single arm, open label, single center clinical trial to evaluate the safety, tolerability, efficacy, pharmacokinetic or pharmacodynamic characteristics of the investigational drug V001-BCMA in autoimmune disease.
Phase: EARLY_PHASE1 • Sponsor: Tongji Hospital • Aim: Disease control
Last updated Jun 27, 2026 08:11 UTC
-
New hope for liver metastases: combo therapy shows promise in early trial
Disease control Recruiting nowThis is a prospective, randomized controlled, single-center phase II clinical study. It aims to compare the efficacy of AK104 plus radiotherapy combined with standard therapy versus standard therapy as first-line treatment for liver metastases from metastatic colorectal cancer.
Phase: PHASE2 • Sponsor: Fudan University • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
New device aims to improve survival in aortic arch surgery
Disease control Recruiting nowThe goal of this clinical trial is to learn if the Arcevo LSA stent graft can safely and effectively treat patients that have an acute or chronic aortic dissection and/or aneurysm that involves the aortic arch and the descending thoracic aorta, with or without the involvement of …
Phase: NA • Sponsor: Artivion Inc. • Aim: Disease control
Last updated Jul 12, 2026 00:00 UTC
-
AI-Powered MRI could spot breast cancer earlier in High-Risk women
Diagnosis Recruiting nowThis is a multi-center, single arm trial to evaluate the cancer detection rate of supplemental screening magnetic resonance imaging (MRI) in participants who are high-risk by Mirai-MRI assessment. Mirai is an accurate cancer risk model based on full-resolution mammograms.
Phase: NA • Sponsor: University of California, San Francisco • Aim: Diagnosis
Last updated Jun 27, 2026 07:56 UTC
-
Could some esophageal cancer patients skip surgery? new trial tests a less invasive option
Disease control Recruiting nowThis is a multi-center, Phase II clinical study aiming to evaluate the efficacy, safety, and organ preservation feasibility of definitive concurrent chemoradiotherapy versus surgery in patients with locally advanced resectable esophageal squamous cell carcinoma (ESCC) who achieve…
Phase: PHASE2 • Sponsor: Tianjin Medical University Cancer Institute and Hospital • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New hope for KRAS-driven lung cancer: drug duo targets tough mutation
Disease control Recruiting nowStudy Design: a Phase II, single-arm, multicenter, prospective, interventional study. Target Population: Subjects with previously untreated, locally advanced or metastatic non-small cell lung cancer (NSCLC) confirmed to harbor the KRAS G12C mutation. Treatment Regimen: All enro…
Phase: PHASE2 • Sponsor: Guangdong Association of Clinical Trials • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
New alpha radiation therapy shows promise for tough prostate cancer
Disease control OngoingThis Phase 1 study will evaluate the safety, tolerability, and preliminary effectiveness of AB001, an alpha-emitting radioligand targeting prostate-specific membrane antigen (PSMA), in patients with advanced prostate cancer who are either 177Lu-PSMA naïve or experienced. The stud…
Phase: PHASE1 • Sponsor: ARTBIO Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC
-
Triple drug cocktail takes on recurrent glioblastoma
Disease control Recruiting nowThis is a multicentric phase II open-label clinical trial aiming to assess the efficacy of the combination of trimipramine and atezolizumab with bevacizumab in patients with recurrent glioblastoma. Eligible patients will be assigned to two cohorts depending on whether there is a …
Phase: PHASE2 • Sponsor: Centre Hospitalier Universitaire Vaudois • Aim: Disease control
Last updated Jun 27, 2026 09:04 UTC
-
New hope for painful skin condition: drug trial targets stubborn HS
Disease control Recruiting nowThis is a double-blind, placebo-controlled study where subjects are participating for approximately 36 to 40 weeks. The study compares how well BFB759 works and how safe it is compared with a placebo.
Phase: PHASE2, PHASE3 • Sponsor: Bluefin Biomedicine, Inc. • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New drug combo targets Hard-to-Treat stomach cancer in early trial
Disease control Recruiting nowThis is a phase 2 study designed to evaluate the safety and efficacy of IBI363 in combination with oxaliplatin and capecitabine (XELOX) or S-1 and oxaliplatin (SOX) in perioprative treatment of locally advanced MHC-II-negative gastric and gastroesophageal junction adenocarcinoma.
Phase: PHASE2 • Sponsor: Zhejiang Cancer Hospital • Aim: Disease control
Last updated Jun 27, 2026 08:09 UTC